Lipid nanoparticles
(LNPs) have emerged across the pharmaceutical
industry as promising vehicles to deliver a variety of therapeutics.
Currently in the spotlight as vital components of the COVID-19 mRNA
vaccines, LNPs play a key role in effectively protecting and transporting
mRNA to cells. Liposomes, an early version of LNPs, are a versatile
nanomedicine delivery platform. A number of liposomal drugs have been
approved and applied to medical practice. Subsequent generations of
lipid nanocarriers, such as solid lipid nanoparticles, nanostructured
lipid carriers, and cationic lipid–nucleic acid complexes,
exhibit more complex architectures and enhanced physical stabilities.
With their ability to encapsulate and deliver therapeutics to specific
locations within the body and to release their contents at a desired
time, LNPs provide a valuable platform for treatment of a variety
of diseases. Here, we present a landscape of LNP-related scientific
publications, including patents and journal articles, based on analysis
of the CAS Content Collection, the largest human-curated collection
of published scientific knowledge. Rising trends are identified, such
as nanostructured lipid carriers and solid lipid nanoparticles becoming
the preferred platforms for numerous formulations. Recent advancements
in LNP formulations as drug delivery platforms, such as antitumor
and nucleic acid therapeutics and vaccine delivery systems, are discussed.
Challenges and growth opportunities are also evaluated in other areas,
such as medical imaging, cosmetics, nutrition, and agrochemicals.
This report is intended to serve as a useful resource for those interested
in LNP nanotechnologies, their applications, and the global research
effort for their development.